Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Moderna Inc. (MRNA:NASDAQ), powered by AI.
Moderna Inc. is currently trading at $55.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Moderna Inc. on Alpha Lenz.
View Moderna Inc.'s valuation metrics on Alpha Lenz.
“Moderna Inc.'s ROE is -28.9%. Explore profitability and growth together.”
Ask for details →Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
“Moderna Inc.'s ROE is -28.9%. Explore profitability and growth together.”
Ask for details →Moderna Inc. (ticker: MRNA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 5,800 employees.
The current price is $55.4 with a P/E ratio of -x and P/B of -x.
ROE is -28.87% and operating margin is -159.94%. Annual revenue is $1.9B.